Analyze Your Search

Hints:

  • Action links for each search result record
    • Bookmark: Allows you to Bookmark the page for easy future retrieval 
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • More Info: Shows full summary of content record
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Follow" button to the right of the search box. 
Pancreatitis and Pancreatic Endocrine Tumors
  Follow Topic   Edit Search
Your search returned 53 results
from the time period: last 90 days.
Sort by Relevance / Date Group By Journal / No Grouping
Gut
Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8(+) T cell number and tumour growth in pancreatic cancer..
Oncology (2)
Pancreatic Neoplasms (2), more mentions
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 
Purpose Gemcitabine is standard of care in the adjuvant treatment of resectable pancreatic ductal adenocarcinoma (PDAC). The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with gemcitabine has shown efficacy in the treatment of advanced PDAC and was considered to improve survival in patients with primarily resectable PDAC after R0 resection. Patients and Methods In an open-label, multicenter trial, patients were randomly assigned to one of two study arms: gemcitabine 1,000 mg/m(2) days 1, 8, 15, every 4 weeks plus erlotinib 100 mg once per day (GemErlo) or gemcitabine (Gem) alone for six cycles. The primary end point of the study was to improve disease-free survival (DFS) from 14 to 18 months by adding erlotinib to gemcitabine. Results In all, 436 patients were randomly assigned at 57 study centers between April 2008 and July 2013. A total of 361 instances (83%) of disease recurrence were observed after a median follow-up of 54 months. Median treatment duration was 22 weeks in both arms. There was no difference in median DFS (GemErlo 11.4 months; Gem 11.4 months) or median overall survival (GemErlo 24.5 months; Gem 26.5 months). There was a trend toward long-term survival in favor of GemErlo (estimated survival after 1, 2, and 5 years for GemErlo was 77%, 53%, and 25% v 79%, 54%, and 20% for Gem, respectively). The occurrence or the grade of rash was not associated with a better survival in the GemErlo arm. Conclusion To the best of our knowledge, CONKO-005 is the first study to investigate the combination of chemotherapy and a targeted therapy in the adjuvant treatment of PDAC. GemErlo for 24 weeks did not improve DFS or overall survival over Gem.
Oncology (1)
Pancreatic Neoplasms (1), Adenocarcinoma (1), more mentions
The American journal of gastroenterology
Abstract: Chronic pancreatitis is a putative risk factor for pancreatic cancer... for observational studies investigating the association between chronic pancreatitis and pancreatic cancer... Pooled EEs for pancreatic cancer in patients with chronic pancreatitis were 16.16 (95% CI: 12.59-20.73) for patients diagnosed with pancreatic cancer within 2 years from their chronic pancreatitis diagnosis ...
Oncology (10)
Pancreatic Neoplasms (10), Chronic Pancreatitis (10), more mentions
Cancer cell 
DescriptorName: Carcinoma, Pancreatic Ductal. DescriptorName: DNA Methylation. DescriptorName: Epigenesis, Genetic. DescriptorName: Gene Expression Profiling. DescriptorName: Gene Expression Regulation, Neoplastic. DescriptorName: Genomics. DescriptorName: Humans. DescriptorName: Mutation. DescriptorName: Pancreatic Neoplasms... Keyword: pancreatic cancer. Keyword: tumor cellularity.
Oncology (1)
Neoplasms (4), Pancreatic Neoplasms (2), Adenocarcinoma (2), more mentions
Proceedings of the National Academy of Sciences of the United States of America 
Only one of the 182 plasma samples from the control cohort was positive for any of the DNA or protein biomarkers (99.5% specificity. This combinatorial approach may prove useful for the earlier detection of many cancer types Keyword: circulating tumor DNA. Keyword: early cancer detection. Keyword: liquid biopsy. Keyword: pancreatic cancer. Keyword: protein biomarkers.
Oncology (6)
Neoplasms (8), Adenocarcinoma (2), Pancreatic Neoplasms (1), more mentions
6. Recent Advances in Endoscopy.  
Date: 06/25/2017
Gastroenterology
In this narrative review, invited by the Editors of Gastroenterology, we summarize recent advances in the field of gastrointestinal endoscopy. We have chosen articles published primarily in the past 2-3 years. Although a thorough literature review was performed for each topic, the nature of the article is subjective and systematic and is based on the authors' experience and expertise regarding articles we believed were most likely to be of high clinical and scientific importance.
Bile Duct Neoplasms (1), Cholangiocarcinoma (1), Pancreatitis (1), more mentions
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Germline Testing for Individuals With Pancreatic Cancer: The Benefits and Challenges to Casting a Wider Net..
Oncology (2)
Pancreatic Neoplasms (2), more mentions
Pancreas
Therapeutic Potential for FGFR Inhibitors in SOX9-FGFR2 Coexpressing Pancreatic Cancer..
Oncology (2)
Pancreatic Neoplasms (2), more mentions
Radiology
Local Ablative Therapy Options for Patients with Inoperable Pancreatic Cancer..
Oncology (2)
Pancreatic Neoplasms (2), more mentions
JAMA surgery
Neoadjuvant Treatment in Locally Advanced and Borderline Resectable Pancreatic Cancer vs Primary Resectable Pancreatic Cancer..
Oncology (4)
Pancreatic Neoplasms (4), more mentions
Pancreas
Assessment of the Utility of Laparoscopy and Peritoneal Cytology in the Staging of Pancreatic Cancer..
Oncology (2)
Pancreatic Neoplasms (2), more mentions
Nature
Upholding a role for EMT in pancreatic cancer metastasis..
Oncology (4)
Pancreatic Neoplasms (2), more mentions
Annals of oncology : official journal of the European Society for Medical Oncology
Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer..
Oncology (2)
Pancreatic Neoplasms (2), more mentions
Gut
Non-coding regulatory variations: the dark matter of pancreatic cancer genomics..
Oncology (2)
Pancreatic Neoplasms (2), more mentions
Nature reviews. Gastroenterology & hepatology 
Pancreatic cancer: Exosomes for targeting KRAS in the treatment of pancreatic cancer..
Oncology (4)
Pancreatic Neoplasms (4), more mentions
Annals of surgical oncology
... of visceral adiposity and sarcopenic visceral obesity on outcomes after resection of pancreatic cancer remains unclear AbstractText: A retrospective analysis of 301 patients who underwent resection for localized pancreatic cancer between 2004 and 2015 was performed ... and quality, were closely associated with mortality and recurrence after resection of pancreatic cancer.
Anti-Obesity and Weight Loss (5), Oncology (5)
Visceral Obesity (5), Pancreatic Neoplasms (4), more mentions
Annals of surgical oncology
PURPOSE: There is debate regarding the definition and clinical significance of margin clearance in pancreatic ductal adenocarcinoma (PDA). A comprehensive archival analysis of surgical resection margins was performed to determine the effect on locoregional recurrence and survival, and the impact of adjuvant therapy in PDA. METHODS: We identified 105 patients with resected PDA. Pancreatic, anterior, bile duct, and posterior surgical resection margins (PM; posterior surface, uncinate and vascular groove) were identified. Three pathologists reviewed all archival surgical specimens and recategorized each margin as tumor at ink/transected, <0.5, 0.5-1, >1-2, or >2 mm from the inked surface. The impact of these and other clinical variables was assessed on local control, disease-free survival (DFS), and overall survival (OS). RESULTS: Among all margins, PM clearance up to 2 mm was prognostic of DFS (p = 0.01) and OS (p = 0.01). Dichotomizing the PM at 2 mm revealed it to be an independent predictor of local recurrence-free survival [hazard ratio HR] 0.20, 95% confidence interval [CI] 0.048-0.881, p = 0.033), DFS (HR 0.46, 95% CI 0.22-0.96, p = 0.03), and OS (HR 0.31, 95% CI 0.14-0.74, p = 0.008). A margin status of >2 mm was also prognostic of OS in patients who received adjuvant chemotherapy (HR 0.31, 95% CI 0.11-0.89, p = 0.03), however this difference was mitigated in patients receiving adjuvant chemoradiotherapy (HR 0.40, 95% CI 0.10-1.58, p = 0.19). CONCLUSION: These data highlight the clinical significance of the PM and the lack of significance of other resection margins. Clearance in excess of 2 mm should be considered to improve long-term clinical outcomes. The use of adjuvant radiotherapy should be strongly considered in patients with PMs <2 mm.
Oncology (1)
Pancreatic Neoplasms (1), Neoplasms (1), Adenocarcinoma (1), more mentions
The British journal of surgery
AbstractText: Despite improvements in diagnostic imaging and staging, unresectable pancreatic cancer is still encountered during surgical exploration with curative intent. This nationwide study investigated outcomes in patients with unresectable pancreatic cancer found during surgical exploration AbstractText: All patients diagnosed with primary ... hazards regression analysis AbstractText: There were 10 595 patients with pancreatic cancer during the study interval.
Oncology (6)
Pancreatic Neoplasms (5), Carcinoma (1), Neoplasms (1), more mentions
The British journal of surgery 
AbstractText: The International Study Group of Pancreatic Surgery (ISGPS) recommends operative exploration and resection of pancreatic cancers in the presence of reconstructable mesentericoportal axis involvement. However, there is no consensus on the ideal method of vascular reconstruction. The effect of depth of tumour invasion of the vessel wall on outcome is also unknown AbstractText: This was a retrospective cohort study ...
Oncology (1)
Pancreatic Neoplasms (1), Adenocarcinoma (1), more mentions
Pancreas
AbstractText: Acute pancreatitis may be the first manifestation of pancreatic cancer... Hence, the rate ratio of pancreatic cancer was almost 9 times higher in patients who developed chronic ... a first episode of acute pancreatitis may be related to pancreatic cancer, this risk is mainly present in patients who progress to ...
Oncology (7)
Pancreatic Neoplasms (7), Chronic Pancreatitis (5), Pancreatitis (5), more mentions
1 2 3  | Next Page»